Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Voyager Therapeutics (VYGR) Leases (2019 - 2025)

Voyager Therapeutics' Leases history spans 7 years, with the latest figure at $28.5 million for Q4 2025.

  • For Q4 2025, Leases fell 14.61% year-over-year to $28.5 million; the TTM value through Dec 2025 reached $28.5 million, down 14.61%, while the annual FY2025 figure was $28.5 million, 14.61% down from the prior year.
  • Leases for Q4 2025 was $28.5 million at Voyager Therapeutics, down from $29.7 million in the prior quarter.
  • Across five years, Leases topped out at $39.2 million in Q1 2024 and bottomed at $13.5 million in Q4 2023.
  • The 5-year median for Leases is $31.6 million (2025), against an average of $26.9 million.
  • The largest annual shift saw Leases plummeted 53.72% in 2022 before it skyrocketed 161.08% in 2024.
  • A 5-year view of Leases shows it stood at $33.5 million in 2021, then tumbled by 53.72% to $15.5 million in 2022, then decreased by 12.75% to $13.5 million in 2023, then surged by 146.85% to $33.3 million in 2024, then decreased by 14.61% to $28.5 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Leases are $28.5 million (Q4 2025), $29.7 million (Q3 2025), and $31.0 million (Q2 2025).